Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in POTS
NCT07585513Phase 2Not yet recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mirabegron in postural orthostatic tachycardia syndrome (POTS), sponsored by Cedars-Sinai Medical Center. Planned start May 2026; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT07585513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585513.